Most of polyamino acid-based therapeutics are in the early stages of research phases or Proof of Concept (POC) with limited examples marketed or in clinical phases. This is in partly due to the long journey of the candidates from feasibility stage at R&D level to the market that must be performed along with Good Manufacturing Practice (GMP) regulation. This implies the careful planification of the Chemistry Manufacturing and Control (CMC) activities that must be applied to support, control, and secure the journey.<br/>We have developed the capabilities and methods to provide support from development and optimization of polymer-based drug delivery systems through the manufacturing of GMP supply to support clinical trials and commercial drug substance and drug products. In this regard, at Curapath, we are experts in providing complete CMC packages that go all the way from development-optimization and performance of the manufacturing process of drug substances and drug products and analytical methods till managing the packaging, labelling and shipments of products.

From feasibility stage to the market: CMC to support and secure the journey

Where thousands of chemistry professionals meet to share ideas and advance scientific and technical knowledge. Spring 2023 abstracts, posters, and presentations will launch at the end of March.

ACS Spring 2023

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.